At the Responsible Investing Symposium, cohosted by Sands Capital and the UVA Darden School of Business, investors, business leaders, and academics explored how to identify what matters most for long-term investors.

In her remarks to the International Corporate Governance Network (ICGN) Conference, Sands Capital Director of Stewardship Karin Riechenberg discussed the challenges of creating an AI governance framework.

Sands Capital led CompScience’s $27.6M funding round, paving the way for enhanced AI capabilities, an expanded global team, deeper insurer partnerships, and extended reach into new industries.

Sands Capital led Cytovale’s $100 million Series D funding round, enabling commercial and operational expansion of IntelliSep, a rapid diagnostic test cleared by the Federal Drug Administration (FDA), that is transforming sepsis care for hospital emergency departments and health systems nationwide.

This latest funding will help enable the company’s continued growth, enhanced processes, upgraded tooling, expanded infrastructure, and increased supply chain resiliency.

The United Kingdom’s Financial Reporting Council has named Sands Capital as a signatory to the UK Stewardship Code for the second year in a row. The UK Stewardship Code was designed to strengthen reporting requirements and stewardship expectations for asset managers, asset owners, and service providers.

Managing a team of analysts is no easy task, explains Michael Raab. It’s a diverse opinionated group charged with creating the investment ideas that can add value for clients. Cultivating a culture that supports this creativity is an ongoing endeavor.

Talented students from universities across the country will be supporting the investment, operations, and client service teams as part of Sands Capital’s summer internship program.

Sands Capital closed Pulse Fund III, securing $555 million to invest in groundbreaking therapeutics, diagnostics, and life sciences tools with the potential to advance disease understanding and treatment.